1.
Bioorg Med Chem Lett
; 11(14): 1911-4, 2001 Jul 23.
Artículo
en Inglés
| MEDLINE
| ID: mdl-11459659
RESUMEN
This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.